Home › Therapeutic areas › Oncology › Bladder Cancer
Bladder Cancer (11 companies)
Companies with an active program in Bladder Cancer.
| Ticker | Company | Therapeutic areas | Programs | Lead stage | Mkt cap | Programs |
|---|---|---|---|---|---|---|
| AKTS | Aktis Oncology | Oncology | 1 | Phase 1 | $880M | 10 |
| ARTV | Artiva Biotherapeutics | Oncology | 1 | — | $203M | 6 |
| BCYC | Bicycle Therapeutics | Oncology | 2 | Phase 2 | $253M | 4 |
| CGON | CG Oncology | Oncology | 1 | NDA Submitted | $6.79B | 1 |
| EXEL | Exelixis | CardiovascularOncology | 1 | Approved | $17.0B | 23 |
| IBRX | ImmunityBio | Infectious DiseaseOncology | 2 | Approved | $9.15B | 16 |
| NKTR | Nektar Therapeutics | DermatologyImmunology+2 | 1 | Phase 3 | $1.27B | 11 |
| TARA | Protara Therapeutics | DermatologyMetabolic+1 Rare | 1 | Phase 3 | $142M | 3 |
| RLMD | Relmada Therapeutics | MetabolicNeurology+1 Rare | 1 | Phase 2 | $416M | 4 |
| SMMT | Summit Therapeutics | Oncology | 1 | NDA Submitted | $13.1B | 6 |
| TYRA | Tyra Biosciences | MetabolicOncology Rare | 2 | Phase 2 | $1.26B | 5 |
No companies match.